Corcept Therapeutics Incorporated (0I3Q.L)
USD 55.58
(-0.47%)
USD 55.58
(-0.47%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 151 Thousand USD | -86.79% |
| 2022 | 1.14 Million USD | 117.3% |
| 2021 | 526 Thousand USD | -79.38% |
| 2020 | 2.55 Million USD | -26.29% |
| 2019 | 3.46 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 14.66 Million USD | -2.01% |
| 2015 | 14.96 Million USD | 58.8% |
| 2014 | 9.42 Million USD | 64.1% |
| 2013 | 5.74 Million USD | 116.72% |
| 2012 | 2.65 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 6000.00 USD | -62.5% |
| 2008 | 16 Thousand USD | -44.83% |
| 2007 | 29 Thousand USD | -30.95% |
| 2006 | 42 Thousand USD | -22.22% |
| 2005 | 54 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 523.68 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 76 Thousand USD | -49.67% |
| 2024 Q3 | 6.79 Million USD | 19.79% |
| 2024 Q2 | 5.66 Million USD | 7359.21% |
| 2023 FY | 151 Thousand USD | -86.79% |
| 2023 Q3 | 225 Thousand USD | -24.24% |
| 2023 Q4 | 151 Thousand USD | -32.89% |
| 2023 Q1 | 575 Thousand USD | -49.69% |
| 2023 Q2 | 297 Thousand USD | -48.35% |
| 2022 Q4 | 1.14 Million USD | -33.04% |
| 2022 Q1 | 2.81 Million USD | 435.36% |
| 2022 FY | 1.14 Million USD | 117.3% |
| 2022 Q2 | 2.26 Million USD | -19.6% |
| 2022 Q3 | 1.7 Million USD | -24.6% |
| 2021 FY | 526 Thousand USD | -79.38% |
| 2021 Q2 | 1.55 Million USD | -24.58% |
| 2021 Q1 | 2.06 Million USD | -18.97% |
| 2021 Q4 | 526 Thousand USD | -49.71% |
| 2021 Q3 | 1.04 Million USD | -32.91% |
| 2020 Q3 | 3.03 Million USD | -13.52% |
| 2020 Q1 | 3.11 Million USD | -10.08% |
| 2020 Q2 | 3.5 Million USD | 12.63% |
| 2020 Q4 | 2.55 Million USD | -15.84% |
| 2020 FY | 2.55 Million USD | -26.29% |
| 2019 FY | 3.46 Million USD | 0.0% |
| 2019 Q2 | 1.14 Million USD | -24.52% |
| 2019 Q1 | 1.52 Million USD | 0.0% |
| 2019 Q3 | 770 Thousand USD | -32.93% |
| 2019 Q4 | 3.46 Million USD | 349.48% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 Q2 | 4.57 Million USD | -54.75% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q1 | 10.1 Million USD | -31.08% |
| 2016 Q3 | 18.72 Million USD | -16.04% |
| 2016 Q4 | 14.66 Million USD | -21.69% |
| 2016 Q1 | 16.32 Million USD | 9.07% |
| 2016 FY | 14.66 Million USD | -2.01% |
| 2016 Q2 | 22.3 Million USD | 36.63% |
| 2015 FY | 14.96 Million USD | 58.8% |
| 2015 Q3 | 13.5 Million USD | 12.24% |
| 2015 Q1 | 10.65 Million USD | 13.09% |
| 2015 Q4 | 14.96 Million USD | 10.79% |
| 2015 Q2 | 12.03 Million USD | 12.91% |
| 2014 Q2 | 7.39 Million USD | 7.25% |
| 2014 Q1 | 6.89 Million USD | 20.08% |
| 2014 FY | 9.42 Million USD | 64.1% |
| 2014 Q4 | 9.42 Million USD | 8.81% |
| 2014 Q3 | 8.66 Million USD | 17.1% |
| 2013 Q1 | 3.9 Million USD | 47.17% |
| 2013 FY | 5.74 Million USD | 116.72% |
| 2013 Q2 | 3.65 Million USD | -6.41% |
| 2013 Q3 | 4.5 Million USD | 23.29% |
| 2013 Q4 | 5.74 Million USD | 27.62% |
| 2012 FY | 2.65 Million USD | 0.0% |
| 2012 Q4 | 2.65 Million USD | -91.33% |
| 2012 Q3 | 30.57 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | -100.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q1 | 4000.00 USD | -33.33% |
| 2009 Q4 | 6000.00 USD | -33.33% |
| 2009 Q1 | 14 Thousand USD | -12.5% |
| 2009 Q2 | 12 Thousand USD | -14.29% |
| 2009 Q3 | 9000.00 USD | -25.0% |
| 2009 FY | 6000.00 USD | -62.5% |
| 2008 Q2 | 23 Thousand USD | -11.54% |
| 2008 Q4 | 16 Thousand USD | -15.79% |
| 2008 Q3 | 19 Thousand USD | -17.39% |
| 2008 Q1 | 26 Thousand USD | -10.34% |
| 2008 FY | 16 Thousand USD | -44.83% |
| 2007 Q4 | 29 Thousand USD | -12.12% |
| 2007 FY | 29 Thousand USD | -30.95% |
| 2007 Q2 | 35 Thousand USD | -10.26% |
| 2007 Q3 | 33 Thousand USD | -5.71% |
| 2007 Q1 | 39 Thousand USD | -7.14% |
| 2006 Q2 | 48 Thousand USD | -5.88% |
| 2006 FY | 42 Thousand USD | -22.22% |
| 2006 Q3 | 45 Thousand USD | -6.25% |
| 2006 Q4 | 42 Thousand USD | -6.67% |
| 2006 Q1 | 51 Thousand USD | -5.56% |
| 2005 Q2 | 10 Thousand USD | 0.0% |
| 2005 Q3 | 45 Thousand USD | 350.0% |
| 2005 Q4 | 54 Thousand USD | 20.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | 54 Thousand USD | 0.0% |
| 2004 Q1 | 528.89 Thousand USD | 0.99% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | 523.68 Thousand USD | 0.0% |
| 2003 Q4 | 523.68 Thousand USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 99.587% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.941% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 99.636% |
| Perrigo Company plc | 4.07 Billion USD | 99.996% |
| Illumina, Inc. | 2.26 Billion USD | 99.993% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 100.0% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 84.9% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.998% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.999% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.913% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.994% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 99.441% |
| Waters Corporation | 2.35 Billion USD | 99.994% |
| Biogen Inc. | 7.33 Billion USD | 99.998% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 99.604% |
| Evolus, Inc. | 126.54 Million USD | 99.881% |
| Adicet Bio, Inc. | 17.7 Million USD | 99.147% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 99.65% |
| bluebird bio, Inc. | 330.32 Million USD | 99.954% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.972% |
| FibroGen, Inc. | 170.45 Million USD | 99.911% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.994% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 99.277% |
| Homology Medicines, Inc. | 44.05 Million USD | 99.657% |
| Geron Corporation | 85.89 Million USD | 99.824% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.994% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.966% |
| Myriad Genetics, Inc. | 145 Million USD | 99.896% |
| Viking Therapeutics, Inc. | 1.26 Million USD | 88.016% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 99.869% |
| Zoetis Inc. | 6.8 Billion USD | 99.998% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 96.57% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.993% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.987% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.981% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 99.584% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.99% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 99.739% |
| Verastem, Inc. | 41.55 Million USD | 99.637% |
| Nektar Therapeutics | 230.4 Million USD | 99.934% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 99.919% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 95.088% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.989% |
| OPKO Health, Inc. | 326.56 Million USD | 99.954% |
| Exelixis, Inc. | 189.94 Million USD | 99.921% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.965% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 99.891% |
| Imunon, Inc. | 1.13 Million USD | 86.746% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.98% |
| Insmed Incorporated | 1.2 Billion USD | 99.987% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.99% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 99.735% |
| TG Therapeutics, Inc. | 110.79 Million USD | 99.864% |
| Incyte Corporation | 38.28 Million USD | 99.606% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 99.983% |